BELGRADE, Mont., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that management will participate in two upcoming investor conferences:
Jefferies London Healthcare Conference – November 14-16
A live webcast of the Jefferies presentation will be available on the Investors section of the Company’s website at www.xtantmedical.com. A replay of the webcast will be available following the conclusion of the presentation.
14th Annual Craig-Hallum Alpha Select Conference – November 16
About Xtant Medical Holdings, Inc.
Xtant Medical’s mission of honoring the gift of donation so that our patients can live as full and complete a life as possible, is the driving force behind our company. Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.
The symbols™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.
Investor Relations Contact
David Carey
Lazar FINN
Ph: 212-867-1762
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.36 |
Daily Change: | 0.0017 0.47 |
Daily Volume: | 174,404 |
Market Cap: | US$50.040M |
November 12, 2024 September 23, 2024 September 18, 2024 August 08, 2024 August 08, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB